NI
CASC

Numeric Investors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Numeric Investors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-22,017
Closed -$494K – 1246
2015
Q2 		$494K Buy
+22,017
New +$348K 0.01% 680

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Numeric Investors's CASC Position: Q3 2015 in Review

Numeric Investors sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 22,017 shares — an estimated $494K sold.

Numeric Investors first reported a position in CASC in Q2 2015 and held it in 1 quarter. The position peaked at $494K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • Numeric Investors reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Numeric Investors sold 22,017 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $494K.
  • Numeric Investors first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Numeric Investors's Cascadian Therapeutics, Inc. position peaked at $494K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Numeric Investors's 13F filing for Q3 2015, filed 12 Nov 2015.